A phase IV, multicenter, open label, single-arm, 48-week study analyzing suitability of BIC/FTC/TAF for the rapid initiation of ART in naive individuals infected with HIV
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms BICNOW
- 16 Dec 2022 New trial record